Response of plasma prorenin and active renin to chronic and acute alterations of renin secretion in normal humans. Studies using a direct immunoradiometric assay.
Abstract:We employed a novel immunoradiometric assay to measure plasma levels of active renin and prorenin in physiologic and pharmacologic studies designed to characterize renin biosynthesis and processing in response to both chronic and acute stimuli of renin secretion in normal human subjects. Stimulation of renin secretion with prolonged dietary sodium restriction or amiloride resulted in marked increases in the plasma levels of prorenin, active renin, and plasma renin activity (PRA); suppression of renin secretion… Show more
“…Levels of prorenin were significantly increased from baseline to a similar extent with both irbesartan and aliskiren treatments, an expected consequence of any chronic stimulus of renin release. 30 Measurements of a large panel of biomarkers of inflammation and cardiovascular risk showed few statistically significant differences from baseline levels. Only the inflammatory mediator eotaxin 31 showed a statistically significant between-treatment difference, but the clinical significance of this finding is uncertain.…”
Metabolic syndrome, a cluster of risk factors that increase the risk of cardiovascular morbidity and mortality, is common in patients with hypertension. Chronic renin-angiotensin-aldosterone system (RAAS) activation, shown by elevated plasma renin activity (PRA), is implicated in many of the features of metabolic syndrome. The direct renin inhibitor aliskiren may be of benefit in this patient group as aliskiren targets the RAAS at the rate-limiting step. In this double-blind study, 141 patients with hypertension (mean baseline BP 155/93 mm Hg) and metabolic syndrome (modified National Cholesterol Education Program ATP III criteria) were randomized to aliskiren 300 mg or irbesartan 300 mg once daily. Patients treated with aliskiren 300 mg had their mean sitting blood pressure (BP) lowered by 13.8/ 7.1 mm Hg after 12 weeks, significantly greater (Pp0.001) than the 5.8/2.8 mm Hg reduction observed in patients treated with irbesartan 300 mg. A significantly greater proportion of patients treated with aliskiren achieved BP control to o135/85 mm Hg (29.2 vs 16.7% with irbesartan; P ¼ 0.019). Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both Po0.001). Aliskiren and irbesartan had similar effects on glucose and lipid profiles and on a panel of biomarkers of inflammation and cardiovascular risk. Both aliskiren and irbesartan were well tolerated. Collectively, these results suggest that aliskiren 300 mg may offer treatment benefits compared with irbesartan 300 mg for BP reduction in patients with hypertension and metabolic syndrome.
“…Levels of prorenin were significantly increased from baseline to a similar extent with both irbesartan and aliskiren treatments, an expected consequence of any chronic stimulus of renin release. 30 Measurements of a large panel of biomarkers of inflammation and cardiovascular risk showed few statistically significant differences from baseline levels. Only the inflammatory mediator eotaxin 31 showed a statistically significant between-treatment difference, but the clinical significance of this finding is uncertain.…”
Metabolic syndrome, a cluster of risk factors that increase the risk of cardiovascular morbidity and mortality, is common in patients with hypertension. Chronic renin-angiotensin-aldosterone system (RAAS) activation, shown by elevated plasma renin activity (PRA), is implicated in many of the features of metabolic syndrome. The direct renin inhibitor aliskiren may be of benefit in this patient group as aliskiren targets the RAAS at the rate-limiting step. In this double-blind study, 141 patients with hypertension (mean baseline BP 155/93 mm Hg) and metabolic syndrome (modified National Cholesterol Education Program ATP III criteria) were randomized to aliskiren 300 mg or irbesartan 300 mg once daily. Patients treated with aliskiren 300 mg had their mean sitting blood pressure (BP) lowered by 13.8/ 7.1 mm Hg after 12 weeks, significantly greater (Pp0.001) than the 5.8/2.8 mm Hg reduction observed in patients treated with irbesartan 300 mg. A significantly greater proportion of patients treated with aliskiren achieved BP control to o135/85 mm Hg (29.2 vs 16.7% with irbesartan; P ¼ 0.019). Aliskiren treatment led to a 60% decrease in PRA from baseline, whereas irbesartan increased PRA by 99% (both Po0.001). Aliskiren and irbesartan had similar effects on glucose and lipid profiles and on a panel of biomarkers of inflammation and cardiovascular risk. Both aliskiren and irbesartan were well tolerated. Collectively, these results suggest that aliskiren 300 mg may offer treatment benefits compared with irbesartan 300 mg for BP reduction in patients with hypertension and metabolic syndrome.
“…Renin catalyzes the cleavage of angiotensinogen to angiotensin I, which in turn is cleaved by the angiotensin converting enzyme to its active form angiotensin II. 53,54 The appropriate stimulus for renin production by the kidney is glomerular hypoperfusion. 53 Angiotensin II acts via the specific angiotensin II receptors AT1 and AT2.…”
Summary: Ischemic stroke causes brain damage by multiple pathways. Previous stroke trials have demonstrated that drugs targeting one or only a few of these pathways fail to improve clinical outcome after stroke. Drugs with multimodal actions have been suggested to overcome this challenge. In this review, we describe the mechanisms of action of agents approved for secondary prevention of ischemic stroke, such as antiplatelet, antihypertensive, and lipid-lowering drugs. These drugs exhibit considerable properties beyond their classical mechanisms, including neuroprotective and neuroregenerative properties. In addition, candidate stroke drugs currently studied in clinical phase III trials are described. Among these, albumin, hematopoietic growth factors, and citicoline have been identified as promising agents with multiple mechanisms. These drugs offer hope that additional treatment options for the acute phase after a stroke will become available in the near future.
“…The concentration of active renin was measured by an immunoradiometric assay kit (Diagnostics Pasteur, Marnes La Coquette, France) that uses two monoclonal antibodies against human renin (3E8 and 4G1), as previously described. 26 - 27 Briefly, the first antibody, 3E8, covalently linked to magnetic particles, binds both active and inactive renin, whereas the second antibody, 4G1, labeled with iodine-125, specifically recognizes active renin immobilized by 3E8. Antibody 4G1 did not bind 1) prorenin purified from human kidney or chorionic fluid, 2) prorenin produced by chorionic cells in culture, 3) six distinct synthesized renin fragments, or 4) related proteins such as pepsin or cathepsin D. 27 Immunoradiometric assay results were derived from a standard curve obtained by using monkey serum renin calibrated in Medical Research Council units.…”
Section: Radioimmunoassaysmentioning
confidence: 99%
“…26 - 27 Briefly, the first antibody, 3E8, covalently linked to magnetic particles, binds both active and inactive renin, whereas the second antibody, 4G1, labeled with iodine-125, specifically recognizes active renin immobilized by 3E8. Antibody 4G1 did not bind 1) prorenin purified from human kidney or chorionic fluid, 2) prorenin produced by chorionic cells in culture, 3) six distinct synthesized renin fragments, or 4) related proteins such as pepsin or cathepsin D. 27 Immunoradiometric assay results were derived from a standard curve obtained by using monkey serum renin calibrated in Medical Research Council units. The limit of detection was 5 pg/ml, the intra-assay coefficient of variation (CV) was 6% (n = 10), and the interassay CV was 10% (n=20).…”
The local renin-angiotensin system may regulate adrenal cell growth and function. Angiotensinogen, renin, and angiotensin converting enzyme gene expression were studied in four normal adrenal glands (removed from patients with renal carcinomas) and five aldosterone-secreting adenomas. Northern blot analysis showed expression of angiotensinogen messenger RNA (mRNA) in normal adrenals at levels approximately 35 -fold lower than liver and sixfold lower than kidney. Similar angiotensinogen mRNA levels were present in two aldosteronomas, whereas a third had levels approximately 50% of those found in kidney. Renin mRNA was detectable in most normal adrenals and in three adenomas, one of which had relatively high renin mRNA levels. Angiotensin converting enzyme gene was expressed in adrenal tissue and in three adenomas. Portions from these normal adrenals and two of these aldosteronomas, as well as samples from two other adrenals and three aldosteronomas, were also studied in an in vitro supervision system coupled with active renin radioimmunometric assay, angiotensin II/HI, and aldosterone radioimmunoassay. Total amounts of active renin and angiotensin II/IH released from normal adrenals during 270 minutes of supervision were higher than the amounts released from aldosteronomas (312±35 versus 187+43 and 823±100 versus 436±55 pg/100 mg tissue, respectively; mean±SEM, p<0.05), whereas aldosterone release from the adenomatous tissue was approximately threefold higher (320±21 versus 115±18 ng/100 mg tissue; mean±SEM, p<0.01). Total amounts of active renin and angiotensin II/IH released by normal or adenomatous adrenal samples exceeded threefold to fourfold the amounts extracted from similar samples of the same surgical specimen. These findings provide evidence for a local renin-angiotensin system in human adrenals and in at least some aldosteronomas. (Hypertension 1992;19:702-707) KEY WORDS • angiotensinogen • renin • angiotensin II • adrenal glands • aldosterone • human studies • angiotensin converting enzyme T he renin-angiotensin system (RAS) has been considered as an endocrine system whose components are synthesized by different organs and interact in the circulation to generate the active peptide angiotensin II (Ang II), which then reaches target cells. In the past decade, several studies conducted on animals found evidence for a complete RAS within various tissues, suggesting that locally generated Ang II may act as an autocrine or paracrine mediator that might be independently regulated from circulating RAS.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.